Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma
Acupuncture Use in BC Predicted by Social Determinants of Health
Variability Found in PROs, Gene Expression During AML Induction Chemo
Blinatumomab-Linked ICANS Cases Higher Than Previously Reported